Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Vosoritide Vial vs Pen in Healthy Adults
NCT05813314Phase 1Terminated
- Sponsor
- BioMarin Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vosoritide in achondroplasia (ACH) (2 arms), sponsored by BioMarin Pharmaceutical. Primary endpoints: Maximum observed drug concentration, Area under the concentration versus time curve from time 0 to infinity and 1 more. Started Mar 2023; status: terminated.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT05813314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05813314.